Patricia Spilman advances small-molecule therapeutics and translational biomarkers for neurodegenerative disease. Her work spans biological assay development, extracellular-vesicle pathway modulation, and integrated multiomics, aligned with biopharmaceutics and drug-delivery considerations toward preclinical proof-of-concept.